IDEAYA Biosciences Inc. (NASDAQ: IDYA) announced updated guidance for its Phase 2/3 OptimUM-02 trial of darovasertib in first-line HLA-A2*-negative metastatic ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE